AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$TWST

Twist Bio slips despite Q4 beat after underwhelming FY27 outlook

Twist Bioscience (TWST) reported Q4 FY26 revenue of $126.6M, beating estimates, but shares fell due to weak fiscal 2027 guidance. The company's outlook disappointed investors despite the quarterly beat.

Original reporting
seekingalpha.com
Published Nov 12, 2026, 2:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 2:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TWST
Bearish
high confidence
Mentioned
$TWST
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$TWSTBearishMed
01

Why it matters

The underwhelming FY27 outlook outweighs the revenue beat, prompting a sell‑off.

02

Market read

Earnings and guidance release directly affect TWST price action.

03

What to watch

Potential upside from upcoming product pipelines not reflected in guidance.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Twist Bioscience is a synthetic biology company focused on DNA‑based products.

Company-level read

Ticker impact

$TWSTBearishHigh confidence
Context

Twist Bioscience reported Q4 FY26 revenue of $126.6M and issued underwhelming FY27 guidance, causing a sharp pre‑market price drop.

Expected impact

likely pressure as the market prices in the weaker FY27 outlook

Evidence & confidence

The new FY27 guidance is below expectations, triggering a sell‑off in pre‑market trading.

Market effects

Sector

Synthetic biology sector may see broader weakness as guidance concerns spread.

Regional

US biotech investors could see short‑term pullback.

Global

Limited to investors tracking biotech earnings.

Counterpoint

What could challenge this read

If the market overreacts, the stock could rebound on the revenue beat.

Key entities

  • Company
    Twist Bioscience

    Synthetic biology firm reporting Q4 results.

Read at source← All news

Related articles

$TWSTMedAI 8/10

Twist Bioscience: Fiscal Q4 Earnings Snapshot

Twist Bioscience Corp. (TWST) reported a Q4 loss of $20.6M, or 32 cents per share, with revenue of $126.6M, exceeding estimates. Annual loss was $130.2M, or $2.08 per share, on revenue of $459.4M. The company forecasts Q1 revenue of $130M-$132M and full-year revenue of $550M-$560M.

finance.yahoo.com
$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience (TWST) stock fell 7.1% in pre-market trading after reporting a wider-than-expected Q4 2026 loss of $0.44 per share, despite revenue slightly above estimates at $124.8 million. Analysts had anticipated a loss of $0.38 per share on revenue of $123.6 million. The miss, combined with a bearish report, high short interest, and a declining market, contributed to the decline. The NASDAQ and S&P 500 also fell 0.9% and 0.4%, respectively.

investing.com
$TWSTMed

Twist Bioscience Reports 22% Fiscal 2026 Revenue Growth to $459.4 Million

Twist Bioscience reported fiscal 2026 revenue of $459.4 million, up 22% YoY, and Q4 revenue of $126.6 million, up 28%. Gross margin improved to 52.4%, and adjusted EBITDA reached $2.2 million in Q4. The company forecast fiscal 2027 revenue of $550M-$560M. Twist shipped products to 4,100 customers and 1.3M genes in fiscal 2026, expanding its portfolio with new services and products.

tradingview.com
$TWSTHighAI 8/10

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial Results

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial Results — Record revenue of $459.4 million in Fiscal 2026; Increase of 22% over $376.6 million in Fiscal 2025 — — Record revenue of $126.6 million in 4QFY26 ; Increase of approximately

SEC EDGAR 8-K